MacroGenics (MGNX) Stock Forecast & Price Target

$3.57 -0.24 (-6.30%)

(As of 11/15/2024 ET)

MacroGenics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 11 Analyst Ratings

Sell
0

Hold
8

Buy
3

Based on 11 Wall Street analysts who have issued ratings for MacroGenics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 11 analysts, 8 have given a hold rating, 2 have given a buy rating, and 1 has given a strong buy rating for MGNX.

Consensus Price Target

$7.63
113.59% Upside

According to the 11 analysts' twelve-month price targets for MacroGenics, the average price target is $7.63. The highest price target for MGNX is $14.00, while the lowest price target for MGNX is $4.00. The average price target represents a forecasted upside of 113.59% from the current price of $3.57.

Get the Latest News and Ratings for MGNX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MacroGenics and its competitors.

MGNX Analyst Ratings Over Time

Type	Current Forecast 11/18/23 to 11/17/24	1 Month Ago 10/19/23 to 10/18/24	3 Months Ago 8/20/23 to 8/19/24	1 Year Ago 11/18/22 to 11/18/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	4 Buy rating(s)
Hold	8 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$7.63	$8.11	$8.11	$11.83
Forecasted Upside	113.59% Upside	102.27% Upside	128.48% Upside	55.91% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

Strange: Why is Amazon suddenly yielding 39.70%? (Ad)

Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%!

Click here to see this breakthrough before everyone else →

MGNX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MGNX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

MacroGenics Stock vs. The Competition

Type	MacroGenics	Medical Companies	S&P 500
Consensus Rating Score	2.36	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	113.59% Upside	28,534.46% Upside	9.87% Upside
News Sentiment Rating	Positive News See Recent MGNX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/7/2024	JMP Securities 2 of 5 stars	S. Tuerkcan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
11/6/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00	+6.10%
9/16/2024	Evercore ISI 2 of 5 stars	R. Department Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/15/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$16.00 ➝ $14.00	+319.16%
8/7/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Darout Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Perform ➝ Market Perform	$8.00 ➝ $5.00	+44.51%
8/1/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Pohlman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
Get the Latest News and Ratings for MGNX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.
7/31/2024	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$18.00 ➝ $5.00	-4.76%
7/31/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Schmidt Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$14.00 ➝ $9.00	+65.44%
5/10/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$29.00 ➝ $7.00	-52.28%
5/10/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
11/22/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:44 AM ET.

MGNX Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for MacroGenics is $7.63, with a high forecast of $14.00 and a low forecast of $4.00.
: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 8 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MGNX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MGNX, but not buy additional shares or sell existing shares.
: According to analysts, MacroGenics's stock has a predicted upside of 113.59% based on their 12-month stock forecasts.
: Over the previous 90 days, MacroGenics's stock had 1 upgrade and 1 downgrade by analysts.
: MacroGenics has been rated by research analysts at Evercore ISI, HC Wainwright, and JMP Securities in the past 90 days.
: Analysts like MacroGenics less than other "medical" companies. The consensus rating for MacroGenics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MGNX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

This page (NASDAQ:MGNX) was last updated on 11/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MacroGenics (MGNX) Stock Forecast & Price Target